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Summary. Forearm bone mineral content (BMC), as evaluated 
by photonabsorption densitometry, was measured in 28 cadaver 
kidney donor recipients who entered the study 8 weeks postop- 
eratively and were followed up for 18 months. BMC decreased 
significantly (p<0.05) but marginally in placebo-treated pa- 
tients (n=t4)  (initial BMC 1.09±0.25g/cm; final BMC 
1.05±0.24). Fourteen patients were prophylactically given 
1,25(OH)2vitamin D 3 in a dose which avoided hypercalcemia 
and hypercalciuria (~0.25 gg/day); under 1,25(OH)z vitamin 
D 3 prophylaxis a significant decrease of forearm BMC was 
observed no longer (initial BMC 0.94_+.0.21 g/cm; final BMC 
0.95 +_ 0.21), but the difference between placebo and 1,25(Ott)z 
vitamin D 3 narrowly missed statistical significance (p = 0.066). 
It is concluded that the decrease of forearm BMC is negligi- 
ble in transplant recipients with low steroid regimens. The data 
suggest a trend for prophylaxis with 1,25(OH)z vitamin D 3 
to slightly ameliorate forearm (cortical) BMC loss. 
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Introduction 
Osteopenia is a major complication of steroid therapy [1]. This 
may be particularly true after renal transplantation where ster- 
oids are part of the immunosuppressive regimen [2-5]. Osteo- 
penia represents one major risk thctor in the genesis of avascu- 
lar necrosis of transplanted patients [6, 7]. 
In animal experiments, 1,25(OH)2 vitamin D 3 has been 
shown to diminish the effect of immobilization on the skeleton 
[8] and prophylactic oral 1,25(OH)z vitamin D 3 was shown 
to be effective in preventing lucocorticoid osteopenia in rats 
[9]. In patients chronically treated with supraphysiologic doses 
of glucocorticoids Hahn et al. [10] demonstrated an increase 
of metaphyseal and diaphyseal forearm bone mass with chronic 
administration of 25(OH) vitamin D 3 and calcium. The action 
of vitamin D metabolites i  a pharmacologic one, since 25(OH) 
vitamin D 3 levels [10] and 1,25(OH)z vitamin D 3 levels [11] 
are normal in steorid-treated patients. The beneficial effect of
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pharmacologic doses of vitamin D metabolites may be related 
to the reversal of steroid-induced intestinal malabsorption of 
calcium [I 1] and the associated reversal of hyperparathyroidism 
[12]. It is not unreasonable to expect hat such reversal might 
be particularly beneficial in steroid-treated posturemic patients 
with pre-existent hyperparathyroidism. 
Using forearm bone densitometry [13-15] and other tech- 
niques [16], several authors measured a variable but, on aver- 
age, marked decrease of forearm mineral density in trans- 
planted patients without vitamin D supplements, the average 
annual oss being 5-10% during the first year [2]. 
The present prospective placebo-controlled trial was de- 
signed to examine whether p ophylactic administration of 
1,25(OH)2 vitamin D 3 after renal transplantation prevents bone 
mineral oss as measured by forearm radiodensitometry. 
Patients and Methods 
Patient Selection and Protocol 
From July 1980 to September 1981, 61 patients were trans- 
planted at the University of Heidelberg. All consecutive adult 
graft recipients entered the study 8 weeks after transplantation 
unless they had serum creatinine > 1.8 mg/dl, hypercalcemia, 
or systemic disease. The patients were andomly assigned to 
a treatment or a placebo group with the use of random 
numbers. A total of 38 patients entered the study. Ten patients 
(four in the treatment group, six in the placebo group) were 
withdrawn after randomization for the following reasons: two 
patients developed hypercalcemia nd hyperparathyroidism; 
four rejected their graft and developed renal failure; four left 
Germany and were lost for follow-up. 
Twenty-eight cadaver transplant recipients were followed 
up for 18 months (20 men, eight women, median age: 36 years; 
range: 17-53 years). Prior to transplantation, all patients had 
been on dialysis for a median of 42.1 months (range 1-120 
months). None of the patients had symptomatic bone disease, 
elevated alkaline s rum phosphatase, or hypercalcemia prior 
to transplantation. Vitamin D deficiency was excluded by nor- 
mal 25(OH)vitamin D 3 levels at the time of entry into the study 
(182 ± 75 nmol/l). 
1,25(OH)z Vitamin D 3 Therapy 
The patients received either 0.25 gg 1,25-dihydroxy vitamin D 3 
or placebo. The maximal dose was given that was tolerated 
without hypercalcemia (>2.75mmol/1) or hypercalciuria 
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Table 1. Bone mineral content (g/cm) at various times after t ansplantation 
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2 months 5 months 8 months 11 months 14 months 17 months 20 months A 
init ial -  final 
Placebo 1.09 1.07 t .07 
(n= 14) (0.67-1.38) (0.78-1.38) (0.72-1.50) 
1,25(OH)zD 3 0.94 0.96 0.97 
(n=14) (0.59-1.34) (0.63-1.34) (0.63-1.33) 
1.02 1.06 1.06 1.05 0.04 
(0.6.9-1.45) (0.67-1.43) (0.67-1.43) (0.70-1.40) 
0.97 0.96 0.94 0.95 0.01 
(0.62-1.39) (0.68-1.38) (0.65-1.35) (0.63-1.38) 
Data are given as median (range in parentheses) 
(>12.5 mmol/24 h). With the exception of one patient, who 
tolerated 0.5 [xg/day, all patients received a maintenance dose 
of 0.25 gg/day. Therapy was monitored by measuring serum 
and urinary calcium at 3-weekly intervals during the first 3 
months. Subsequently, serum and urine chemistry was exam- 
ined every 3 months. In addition, at 3-months intervals, iPTH 
[18], urinary cAMP [19], and 25(OH)vitamin D 3 [20] were mea- 
sured, and the bone mineral content determined. 
Steroid Treatment 
The patients received 1,000 mg methylprednisolone on the day 
of operation. In the absence of rejection crises, the steroid dose 
was tapered to a median of 16 mg/day 8 weeks postoperatively. 
Twelve months postoperatively (p.o.), the median maintenance 
steroid dose was 7.5mg methylprednisolone/day (range 
4-12 mg). Eight patients were on an alternate-day schedule. 
Acute rejection crises were treated with 1 g methylpredniso- 
lone i.v. for 1-3 days. The median cumulative steroid dose 
over 18 months was 12.932 mg range (7.276-20.684 mg). The 
median number of rejection crises was 1.5 (range: 0-5); the 
median number of rejection crises in the two groups was not 
different. 
Bone Densitometry 
A bone mineral analyzer (Norland Instruments, Model 178) 
was used with a highly collimated beam of monoenergetic pho- 
tons of a 200 mCi ~31I source. Uniformity of tissue absorption 
was achieved by applying a water-filled moulded rubber bag 
around the forearm. The distance olecranon-styloid process was 
measured. The point of transition between middle and distal 
third of the radius was chosen for measurement. For each deter- 
mination eight measurements were made, and the results were 
averaged. Results were expressed as bone mineral content 
(BMC) in g/cm. In healthy probands, the CV for 12 replicate 
measurements at different days was 1.5%. 
Statistics 
Data are given as median and range. Initial and final BMC 
were compared with the sign test. In addition, relative slopes 
were analyzed after rank transformation using a Kruskat-Wallis 
test for two samples and 1 df 
Results 
At the beginning (2 months p.o.) and end (20 months p.o.) 
of the study, the two groups, i.e. placebo versus 1,25(OH)2 
vitamin D3, were comparable with respect to serum creatinine, 
serum phosphorous, iPTH, and urinary cAMP. In the placebo 
group, median S-Crea was 1.5 mg/dl at 2 months and 20 
months and S-Ca 2.4 and 2.5 mmol/1, respectively. 
In the 1,25(OH)z vitamin D3-treated group, the respective 
values for S-Crea were 1.5 and 1.6mg/dl and for S-Ca 2.3 
and 2.3. In both groups, median activities of alkaline serum 
phosphatase decreased (placebo from 164 to 127U/1; 
1,25(OH)2 vitamin D 3 from 141 to 105). Median urinary Ca 
increased in both groups (placebo from 0.8 to 1.5mmol/l; 
1,25(OH)z vitamin D 3 to 2.6). At 2 and 20 months, the median 
daily prednisolone dose was 12 mg (range: 1(~20) and 6 mg 
(range: 4-8), respectively, in the placebo group and t2mg 
(range: 8-16) vs. 6 mg (range: 4-8) in the 1,25(OH)2 vitamin 
D 3 group. 
BMC at various times after transplantation in placebo- and 
1,25(OH) 2 vitamin D3-treated patients is given in Table 1. 
There was a significant difference (p < 0.05) between initial and 
final BMC in the placebo group, but not in the 1,25(OH)z 
vitamin D3-treated group. After rank transformation, the dif- 
ference of relative slopes for BMC between the two groups 
came close to, but did not reach, statistical significance (p = 
0.066). 
Discussion 
Whereas previous authors [2, 13-16] found a variabte but, on 
average, substantial decrease of forearm BMC in transplanted 
patients, such decrease was marginal, although statistically sig- 
nificant, in the present study. The greater change of BMC in 
previous studies may have been due to several factors, e.g., 
higher steroid dosage, severity of pre-existent hyperparathy- 
roidism, inclusion of patients with impaired graft function, age, 
etc. Steroid dosage is presumably the most important factor 
to explain the above differences. A dose-dependent effect of 
steroids on calcium metabolism is suggested by the failure to 
observe changes of intestinal calcium absorption at less than 
15 mg prednisolone/day [20], while such decrease was readily 
demonstrable at high steroid doses [21]. Following the sugges- 
tions of McGeown [22] steroid doses have been reduced consid- 
erably in recent years and have even been further r duced since 
completion of the present study. 
We found only a marginal, but statistically significant, de- 
crease of BMC in placebo-treated patients. The limited magni- 
tude of decrease is not due to the insensitivity of the photonab- 
sorption technique. In particular, the error of replicate measure- 
ments was quite small (CV 1.5%). 
Cortical bone makes an overriding contribution to BMC 
at the site of our forearm measurements. However, it is spongy 
bone as the metabolically most active osseous tissue with the 
highest urnover rate which decreases most after steroid admin- 
istration [24, 25]. Furthermore, spongy bone is of special impor- 
tance in the genesis of avascular bone necrosis [26]. Loss of 
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spongy bone may not be optimally reflected by measurements 
assessing preferentially cortical bone in patients with renal dis- 
ease [16] or other disease states [27]. In transplanted patients, 
prophylactic administration of t,25(Ott)2 vitamin D 3 tended 
to reduce bone loss when compared with placebo, although 
the difference between placebo and t,25(OH) 2vitamin D 3 did 
not quite reach statistical significance. This finding is in general 
agreement with previous experimental [9]and clinical [10] stu- 
dies in non-renal nimals or subjects. However, given th  small 
magnitude offorearm BMC change in placebo-treated controls, 
this finding is of questionable biologic significance. Conse- 
quently, on the basis of these results it would not appear justi- 
fied to recommend prophylactic administration f 1,25(OH)2 
vitamin D 3 in transplant recipients who have normal renal func- 
tion and are on low maintenance doses of steroids. However, 
a significant reduction i  the incidence of osteonecrosis inrecip- 
ients of renal homografts was noted recently, when a vitamin 
D 2 supplement was administered prophylactically [28]. This 
clinical observation validates the rationale underlying our 
study. 
The tendency to use lower steroid doses is pre umably re- 
sponsible for the diminishing incidence of avascular femoral 
head necrosis. Formerly, it tended to be above 10% [6] but 
has diminished ever since. In 339 patients consecutively trans- 
planted in our center, the incidence of aseptic necrosis was 
4.12% [7], and an incidence below 1% was reported when still 
lower doses of steroids were chosen [20]. In the future, steroid- 
free immunosuppressive regimens may hopefully largely elimi- 
nate the problem in transplanted patients. However, the need 
to reduce secondary hyperparathyroidism andthe attended risk 
of osteopenia will persist for steroid-treated non-renal patients 
[28]. 
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